Medicare Advantage Is Associated with Lower Utilization of Total Joint Arthroplasty
Journal of Bone and Joint Surgery · 2024
DOI: 10.2106/jbjs.23.00507 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Bone and Joint Surgery, 2024. Verfasst von Kelly E Anderson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado. Hauptthemen laut MEDLINE: Medicare Part C, Arthroplasty, Replacement, Knee, Osteoarthritis. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: AHRQ HHS.
Abstract (Originalsprache)
Background
Medicare Advantage (MA) insurers use managed care techniques to review the utilization of medical services and control costs. It is unclear if MA enrollees have a lower utilization of elective surgical procedures such as inpatient hip and knee total joint arthroplasty (TJA), which have traditionally been covered by traditional Medicare (TM) without restrictions.
Methods
We conducted a cross-sectional study using a 20% sample of 2018 TM claims and MA encounter records for 5,300,188 TM enrollees and 1,970,032 MA enrollees who were 65 to 85 years of age. We calculated unadjusted and adjusted differences (controlling for beneficiary and market characteristics) in the incidence of TJA for MA compared with TM, and by MA plan type. Finally, we calculated differences in the time to contact with an orthopaedic surgeon and time to the surgical procedure among enrollees with an osteoarthritis diagnosis.
Results
After controlling for observable characteristics, there was a 15.6% lower incidence of TJA in MA enrollees compared with TM enrollees (p < 0.001). Compared with TM enrollees, health maintenance organization (HMO) enrollees were 28.1% less likely to undergo TJA, controlling for observable characteristics (p < 0.001). From the initial diagnosis, the time to contact with an orthopaedic surgeon and the time to the surgical procedure were also lower among TM enrollees compared with MA enrollees. At 2 years after an osteoarthritis diagnosis, 10.4% of TM enrollees, 7.9% of preferred provider organization (PPO) enrollees, and 5.7% of HMO enrollees had undergone inpatient TJA.
Conclusions
MA coverage was associated with a lower utilization of elective, inpatient hip and knee TJA. MA was also associated with a longer time to orthopaedic surgeon evaluation and surgical procedure. Level of Evidence: Prognostic Level III . See Instructions for Authors for a complete description of levels of evidence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, Colorado.
- Hopkins Business of Health Initiative, Baltimore, Maryland.
- Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland.
- Carey Business School, Johns Hopkins University, Baltimore, Maryland.
- National Bureau of Economic Research, Cambridge, Massachusetts.
- Department of Orthopaedic Surgery, Johns Hopkins University, Baltimore, Maryland.
ORCID-Profile: Kelly E Anderson, Rachel J Wu, Michael Darden, Amit Jain
Förderung
- AHRQ HHS
Zitieren
APA
Anderson, K. E., Wu, R. J., Darden, M., & Jain, A. (2024). Medicare Advantage Is Associated with Lower Utilization of Total Joint Arthroplasty. Journal of Bone and Joint Surgery. https://doi.org/10.2106/jbjs.23.00507
Vancouver
Anderson KE, Wu RJ, Darden M, Jain A. Medicare Advantage Is Associated with Lower Utilization of Total Joint Arthroplasty. Journal of Bone and Joint Surgery. 2024. doi:10.2106/jbjs.23.00507
BibTeX
@article{Anderson2024,
author = {Anderson, Kelly E and Wu, Rachel J and Darden, Michael and Jain, Amit},
title = {Medicare Advantage Is Associated with Lower Utilization of Total Joint Arthroplasty},
journal = {Journal of Bone and Joint Surgery},
year = {2024},
doi = {10.2106/jbjs.23.00507}
}
EUVIMED